Diabetes Drugs and Retinopathy: So Far, It's All About Lowering A1C Level
In this second of a four-part video series, ADA Chief Science and Medical Officer Robert Gabbay, MD, PhD, FACP, says data showing kidney benefits of SGLT2 inhibitors may indicate protection against retinopathy but research is needed.
Recent study results have shown that the SGLT2 inhibitors seem to have protective effects against cardiovascular disease and particularly against heart failure, above and beyond their effects on blood glucose levels.
But so far, no class of diabetes drugs stands out as having a protective effect against the retinopathy associated with diabetes, according to Robert Gabbay, M.D., Ph.D., FACP, chief scientific and medical officer for the American Diabetes Association.
Related: Diabetes Can Lead to Leaky Retinal Blood Vessels, Sudden Blindness
Some early data suggest that there might be some difference among the different classes of diabetes, but “we really don’t know for sure,” Gabbay said in a video interview with Managed Healthcare Executive® this week.
“What we do know, though, is that, in essence, any medication that is going to help lower A1C and get better glucose control lowers the risk of retinopathy,” he said.
Still, Gabbay noted there is some evidence of the SGLT2 inhibitors having some protective effect against kidney disease and that “in some ways, the pathophysiology of renal disease is somewhat analogous to eye disease.”
“They are both diseases of leaky blood vessels,” he noted.
Gabbay added there was old dictum that patients with diabetes who had advanced kidney disease almost certainly had some retinopathy and if they didn’t then the kidney disease was unrelated to their diabetes.
Don’t Overlook the Importance of Annual Dilated Retinal Exams
July 15th 2024The annual dilated retinal exam, a unique tool which uses drops to dilate the pupil, is not just about eye health. It offers a comprehensive view of a member's overall well-being, potentially identifying serious health issues at an early stage.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The active ingredient in Ozempic and Wegovy is linked to nonarteritic anterior ischemic optic neuropathy (NAION), the second most common form of optic neuropathy. This is apparently the first study to link semaglutide to the eye condition.
Read More
